American Gene Technologies International Stock
American Gene Technologies develops bio-safe lentivirus therapies to treat cancer, HIV/AIDS, and other chronic human disorders.
Sign up today and learn more about American Gene Technologies International Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About American Gene Technologies International Stock
American Gene Technologies is a gene and cell therapeutics company with a proprietary lentiviral platform capable of broad applications. It develops bio-safe lentivirus therapies to treat cancer, HIV/AIDS, and other chronic human disorders. The company's mission is to leverage the power of gene and cell therapy to reduce human suffering from serious human diseases. American Gene Technologies was established in 2007 and is headquartered in Rockville, Maryland.
Funding History
| September 2013 | $1.3M |
|---|---|
| October 2014 | $340K |
Management
CEO & Founder
Jeffrey A. Galvin
Press
globenewswire - Jan, 27 2024
Phenylketonuria Market to Hit US$ 1,230.05 Million By 2030lawstreetmedia - Jan, 27 2024
Addimmune Goes Public in Bid to Cure HIVfinance - Jan, 27 2024
10X Capital Venture Acquisition Corp. III Announces Transfer ...wjla - May, 25 2022
American Gene Technologies says clinical trial shows increases in immunity against HIVamericangene - May, 25 2022
American Gene Technologies’ HIV Clinical Trial Shows Blood Markers of Efficacy in Two More PatientsEquityZen Recognized As:
